Currently, he is a member of the Developmental Biology Program and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center and a professor of Neuroscience at Weill Cornell Medical College in New York City, NY.
The clinical trial which already has begun recruiting patients, is expected to receive the FDA's study permission by the end of 2020, with an anticipated start date in 2021.
In long-term studies, Studer demonstrated that these cells are non-tumorigenic, can integrate into the host brain and may serve as functional replacements for the substantia nigra dopamine neurons which die in Parkinson's disease.
The following year, he joined Ronald McKay's lab at the National Institute of Health (NIH) to investigate how neural cells could be isolated, cultured, and differentiated to produce neurons with the aim of restoring brain function in Parkinson's disease mouse models.
[8] In 2000, Studer moved to New York City where he embarked on his own research program at Memorial-Sloan Kettering Cancer Center (MSKCC) with a focus on exploring stem cells and brain repair.
In 2016, Studer became a scientific cofounder of BlueRock Therapeutics, a biotech company to develop induced pluripotent stem cell (iPSC) therapies for degenerative conditions like Parkinson's disease and heart failure.